289042-11-1Relevant articles and documents
Preparation method of rosuvastatin calcium intermediate
-
Paragraph 0004, (2017/10/23)
The invention provides a preparation method of a rosuvastatin calcium intermediate. The preparation method of the rosuvastatin calcium intermediate, namely, the compound shown as formula I in the description comprises the following steps: (1) a compound 5 shown as formula II in the description is generated from 4-fluorobenzaldehyde, methyl isobutyrylacetate and urea under the action of a catalyst; (2) a compound 6 shown as formula III in the description is generated from the compound 5 under the action of potassium persulfate as an oxidizing agent; (3) a compound 7 shown as formula IV in the description is generated from the compound 6, tosyl chloride and N-methyl methanesulfonamide under the action of a catalyst; (4) the target compound shown as the formula I is generated from the compound 7 under the action of a vitride solution as a reducing agent and crystallized with a crystallization solution, and a purified target compound is obtained. The preparation method of the rosuvastatin calcium intermediate has the advantages of low production cost, mild condition and simple and convenient operation.
Synthesis, characterization and crystal structure of N-(4-(4-Fluorophenyl)-5-(hydroxymethyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide
Xu, Jia-Ying,Cheng, Wei-Hua,Zhu, Xun,Wu, Huan-Ling,Wang, Kai
, p. 7766 - 7768 (2015/02/19)
N-[4-(4-Fluorophenyl)-5-(hydroxymethyl)-6-isopropylpyrimidin-2-yl]-N-methylmethane sulfonamide (I), an important intermediate to synthesize rosuvastatin, an HMG-CoA reductase inhibitor. It was prepared from methyl 4-(4-fluorophenyl)-6-isopropyl-2-(methylamino)pyrimidine-5-carboxylate (1) via mesylation by mesyl chloride and sodium tert-pentoxide, then reduction by DIBAL/HCl. The product was characterized by NMR and LC-MS. The crystal structure of compound I was investigated using X-ray diffraction and SHELXTL-97 software. The result indicated that compound I crystallized in the monoclinic system, space group C2/C with a = 29.683(6), b = 7.6290 (15), c = 18.215(4) ?, V = 3451.1 (16) ?3; Z 8.
PREPARATION OF ALKYL 4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONY)AMINO]-PYRIMIDINE-5-CARBOXYLATE AND ITS SUBSEQUENT CONVERSION TO N-[4-(4-FLUOROPHENYL)-5-FORMYL-6-ISOPROPYL PYRIMIDIN-2-YL]-N-METHYLMETHANESULFONAMIDE-A KEY INTERMEDIATE IN THE SYNTHESIS OF ROSUVASTATIN
-
Page/Page column 16, (2008/06/13)
The present invention discloses a novel process to prepare a compound of formula (IIA). By reacting a compound of formula-[D], wherein R1 is C1 to C6 alkyl, preferably R1 is methyl or ethyl, more preferably R1 is methyl ; and R2 is C1 to C8 n-alkyl or branched alkyl, cycloalkyl, phenyl , benzyl or substituted phenyl group, preferably R2 is methyl ; with N-methyl methanesulfonamide and a base, optionally with a salt of N-methyl methanesulfonamide, in suitable solvent(s) , to give a compound of formula (IIA), followed by converting compound of formula (IIA) to a compound for formula -[B], by a known process and finally converting a compound of formula (B) to a compound of formula (II), by a novel process using calcium hypochlorite / TEMPO as an oxidant.